In immunization, PPSV23 alone may be indicated for chronic lung disease, diabetes, chronic heart disease, smoking, and alcoholism in immunocompetent persons under 65.

In immunization, PPSV23 alone may be indicated for chronic lung disease, diabetes, chronic heart disease, smoking, and alcoholism in immunocompetent persons under 65.

• A. PPSV23 alone is never indicated in immunocompetent persons under 65.
• B. PPSV23 alone is indicated for all under 65 with any immunocompromising condition.
• C. PPSV23 alone is indicated for chronic kidney disease only.
• D. PPSV23 alone may be indicated for chronic lung disease, diabetes, chronic heart disease, smoking, and alcoholism.

Answer: (D)

PPSV23 is recommended for certain under-65 adults who are immunocompetent and have chronic conditions or risk factors that raise the chance of invasive pneumococcal disease. The listed conditions—chronic lung disease, diabetes, chronic heart disease, and also lifestyle risks like smoking and alcoholism—are all reasons clinicians may choose PPSV23 in this group because the vaccine covers a broad range of pneumococcal serotypes and provides important protection in these at-risk populations. This is why the statement that PPSV23 alone may be indicated for those conditions is the best fit. The other options overgeneralize or narrow the indication incorrectly: PPSV23 is not “never indicated” in these patients; immunocompromised individuals often require different vaccine strategies (such as PCV13 or sequential PCV and PPSV23), not PPSV23 alone; and limiting the indication to chronic kidney disease only misses the other accepted risk factors listed.

PPSV23 is recommended for certain under-65 adults who are immunocompetent and have chronic conditions or risk factors that raise the chance of invasive pneumococcal disease. The listed conditions—chronic lung disease, diabetes, chronic heart disease, and also lifestyle risks like smoking and alcoholism—are all reasons clinicians may choose PPSV23 in this group because the vaccine covers a broad range of pneumococcal serotypes and provides important protection in these at-risk populations. This is why the statement that PPSV23 alone may be indicated for those conditions is the best fit. The other options overgeneralize or narrow the indication incorrectly: PPSV23 is not “never indicated” in these patients; immunocompromised individuals often require different vaccine strategies (such as PCV13 or sequential PCV and PPSV23), not PPSV23 alone; and limiting the indication to chronic kidney disease only misses the other accepted risk factors listed.